Vigil Neuroscience, a biotech firm, has initiated a Phase 1 clinical trial for Alzheimer's disease (AD) treatment, specifically targeting genetically defined subpopulations1. The drug being tested in this trial is VG-3927, which is the first and only small molecule TREM2 agonist in clinical development4. TREM2 is a receptor expressed on the surface of the brain's immune cells, and its activation is thought to be beneficial in neurodegenerative diseases like AD.
The trial design involves the administration of the drug to healthy volunteers2. However, it's important to note that the FDA has implemented a partial clinical hold on the trial2. The specifics of this hold are not detailed in the provided snippets.
The first participant has already been dosed in this trial1, marking a significant milestone in the progress of the study. The patient population for this trial is not explicitly stated in the snippets, but it can be inferred that it includes healthy volunteers and potentially patients with genetically defined subpopulations of AD.
FDA greenlights Vigil's phase 1 Alzheimer's trial, but not without a partial hold